Mizuho cut shares of Depomed (NYSE:ASRT) from a buy rating to a neutral rating in a research note published on Friday, MarketBeat.com reports. Mizuho currently has $7.00 price objective on the stock, down from their previous price objective of $9.00.
A number of other equities research analysts also recently weighed in on the stock. Zacks Investment Research downgraded shares of Depomed from a buy rating to a hold rating in a research note on Tuesday, October 30th. Janney Montgomery Scott downgraded shares of Depomed from a buy rating to a neutral rating in a research note on Wednesday, August 29th. Finally, Roth Capital reiterated a buy rating on shares of Depomed in a research note on Tuesday, August 21st.
ASRT traded down $0.22 during trading on Friday, reaching $4.99. 1,615,624 shares of the company’s stock were exchanged, compared to its average volume of 1,104,469. Depomed has a fifty-two week low of $4.65 and a fifty-two week high of $9.48.
Depomed Company Profile
Assertio Therapeutics, Inc, a specialty pharmaceutical company, engages in the development, sale, and licensing of products for pain and other central nervous system conditions in the United States. It offers Gralise (gabapentin), an once-daily product for the management of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks in adults; and Zipsor (diclofenac potassium) liquid filled capsule, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults.
Further Reading: Asset Allocation and Your Retirement
Receive News & Ratings for Depomed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Depomed and related companies with MarketBeat.com's FREE daily email newsletter.